Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Advances in Therapy|April 6, 2021
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect ComparisonJörg Trojan, Patrick Mollon, Bruno Daniele, et al.International Journal of Radiation Oncology, Biology, Physics|March 3, 2009
The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer networkAlessia Pica, Robert Miller, Salvador Villà, et al.Leukemia & Lymphoma|May 6, 2014
Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphomaEwa Bednaruk-Młyński, Joanna Pieńkowska, Adam Skórzak, et al.Neuro-Oncology|October 11, 2014
Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer NetworkDamien C Weber, Yucai Wang, Robert Miller, et al.Redox Biology|July 16, 2022
Induction of 2-hydroxycatecholestrogens O-methylation: A missing puzzle piece in diagnostics and treatment of lung cancerClaudia Musial, Narcyz Knap, Renata Zaucha, et al.European Urology|October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 StudySiamak Daneshmand, Renata Zaucha, James W F Catto, et al.Journal of Hepatology|May 17, 2025
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 studyDo-Youn Oh, Aiwu Ruth He, Shukui Qin, et al.International Journal of Radiation Oncology, Biology, Physics|July 22, 2011
The essential role of radiotherapy in the treatment of Merkel cell carcinoma: a study from the Rare Cancer NetworkPirus Ghadjar, Johannes H Kaanders, Philipp Poortmans, et al.The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.NEJM Evidence|February 6, 2024
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo-Youn Oh, Aiwu Ruth He, Shukui Qin, et al.Pageof 4